Bausch Health Co. Inc. (BHC) – StreetInsider.com Reports
-
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
-
Jefferies on BHC (BHC): 'We see this as an extremely positive outcome for BHC and removes a key barrier to executing the spin'
-
Bausch Health Companies (BHC) PT Raised to $12 at RBC Capital
-
Bausch Health Canada (BHC) Announces First Public Drug Plan Listings for UCERIS
-
Bausch Health Co. Inc. (BHC) call put ratio 1 call to 3 puts with a focus on March 9 puts
-
Bausch Health (BHC) Announces a Phase 2 Investigator-Initiated Study of RELISTOR
-
Bausch Health Companies (BHC) PT Raised to $9 at RBC Capital
-
Bausch Health Co. Inc. (BHC) Tops Q4 EPS by 12c; offers guidance
-
Bausch Health Companies (BHC) PT Lowered to $14 at Jefferies
-
Bausch Health (BHC) Announces Board Changes
-
Increasing unusual option volume: TDS AXP XRX LEVI SKLZ ACIC BHC AMSC
-
Increasing unusual call option volume: BHC IRBT TRV TNK SATS NTES ENTG ERIC SAVE GCT
-
Bausch Health (BHC) Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod to Treat UC
-
Bausch Health Co. Inc. (BHC) Tops Q3 EPS by 11c
-
This beaten-down pharmaceutical stock can double, Jefferies says
-
Jefferies Upgrades Bausch Health Companies (BHC) to Buy, 'Expect Catalysts on Horizon to Increase Prob of Spin'
-
Icahn adds to Icahn Enterprises L.P. (IEP), Southwest Gas Holdings, Inc. (SWX) in Q2
-
Increasing unusual call option volume: GNS KBUE YELL TUP MMP BHC
-
Bausch Health Co. Inc. (BHC) Tops Q2 EPS by 12c; Offers Guidance
-
RBC Capital Downgrades Bausch Health Companies (BHC) to Sector Perform
-
Bausch Health (BHC) Enters $600M Financing Facility With KKR (KKR)
-
Bausch + Lomb buys Novartis drugs for $1.75 billion to boost eye-care portfolio
-
Bausch Health Co. Inc. (BHC) to Pay $1.75B for Eye Drug From Novartis (NVS) - WSJ
-
TD Cowen Downgrades Bausch Health Companies (BHC) to Market Perform
-
Bausch Health Co. Inc. (BHC) options active amid wide price movement
-
Increasing unusual put option volume: EVGO BHC KNX HZNP TPX GRAB AMGN
-
Bausch Health Co. Inc. (BHC) Climbs 30%
-
Increasing unusual put option volume: MET BHC IEP BGS RILY TUP
-
Increasing unusual option volume: BHC SQM FTAI RPD MODG MVST IEP EDR
-
Bausch Health Companies (BHC) PT Lowered to $6 at BofA Securities
-
Bausch Health Companies (BHC) PT Lowered to $8 at RBC Capital
-
Bausch Health Co. Inc. (BHC) Reports Q1 Loss of $0.55/sh
-
Increasing unusual put option volume: BHC KDB MCB ISEE ICLN VLY PACW DM AMRS
-
Increasing unusual put option volume: BHC IMGN ICLN ALGM GPN FRC ATUS
-
Bausch Health Co. Inc. (BHC) Announces Board Changes
-
Bausch Health Companies (BHC) PT Raised to $10 at BMO Capital
-
Bausch Health Co. Inc. (BHC) Misses Q4 EPS by 201c
-
Bausch Health Co. Inc. (BHC) Misses Q4 EPS by 201c
-
Carl Icahn trims Cheniere Energy (LNG) in Q4 - 13F
-
Increasing unusual call option volume: EWY AYX UMC RVNC TTM AMBC IGT BHC
-
Bausch Health (BHC): FDA Added Extra Hurdle for Generic Xifaxan - Evercore ISI
-
Bausch Health Co. Inc. (BHC) adds to gains, now up 16.5%
-
Bausch Health Co. Inc. (BHC) jumps higher mid-day
-
Bausch Health Companies (BHC) PT Lowered to $14 at Stifel
-
Bausch Health Companies (BHC) PT Lowered to $35 at Cowen
-
Bausch Health Co. Inc. (BHC) Tops Q3 EPS by 16c; Trims FY Revenue Outlook
-
Bausch Health Co. Inc. (BHC) November weekly option implied volatility into quarter results and outlook
-
Bausch Health Co. Inc. (BHC) November weekly 7 straddle priced into quarter results
-
Increasing unusual call option volume: BHC FDX PLTK XP FREY SNY SAVA SG LAZR
-
Bausch Health Co. Inc. (BHC) Responds to Tentative FDA Approval of Norwich Pharmaceuticals' 200 mg Rifaximin
Back to BHC Stock Lookup
